Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Astrocytoma, IDH-Mutant, Grade 2 · Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant · Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant · Recurrent Astrocytoma, IDH-Mutant · Recurrent Astrocytoma, IDH-Mutant, Grade 3 · Recurrent Astrocytoma, IDH-Mutant, Grade 4 · Recurrent Glioblastoma, IDH-Wildtype

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • City of Hope Comprehensive Cancer Center, Duarte, California, United States

    Contact: Study coordinator (Site Public Contact) · becomingapatient@coh.org · 800-826-4673
    Contact: Principal Investigator (Stephanie M. Yoon)
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

    Contact: Study coordinator (Site Public Contact) · ucstudy@uci.edu · 877-827-8839
    Contact: Principal Investigator (Jerica M. Lomax)
  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Site Public Contact) · cancercto@ucsd.edu · 858-822-5354
    Contact: Principal Investigator (David E. Piccioni)
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

    Contact: Study coordinator (Site Public Contact) · ucstudy@uci.edu · 877-827-8839
    Contact: Principal Investigator (Jerica M. Lomax)
  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

    Contact: Study coordinator (Site Public Contact) · 916-734-3089
    Contact: Principal Investigator (Orwa Aboud)
  • Yale University, New Haven, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Nicholas A. Blondin)
  • Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Nicholas A. Blondin)
  • MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Site Public Contact) · 202-444-2223
    Contact: Principal Investigator (Edina Komlodi-Pasztor)
  • UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Doral, Doral, Florida, United States

    Contact: Study coordinator (Site Public Contact) · kginnity@med.miami.edu
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida, United States

    Contact: Study coordinator (Site Public Contact) · kginnity@med.miami.edu
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Site Public Contact) · 404-778-1868
    Contact: Principal Investigator (Kimberly Hoang)
  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancer@northwestern.edu · 312-695-1301
    Contact: Principal Investigator (Karan Dixit)
  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222
    Contact: Principal Investigator (Steven J. Chmura)
  • Memorial Hospital East, Shiloh, Illinois, United States

  • University of Kansas Clinical Research Center, Fairway, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Tolga Tuncer)
  • University of Kansas Cancer Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Tolga Tuncer)
  • University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Tolga Tuncer)
  • University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

    Contact: Study coordinator (Site Public Contact) · 859-257-3379
    Contact: Principal Investigator (John L. Villano)
  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States

  • Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

  • Washington University School of Medicine, St Louis, Missouri, United States

  • Siteman Cancer Center-South County, St Louis, Missouri, United States

  • Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States

  • NYU Langone Hospital - Long Island, Mineola, New York, United States

    Contact: Study coordinator (Site Public Contact) · cancertrials@nyulangone.org · 212-263-4432
    Contact: Principal Investigator (Marissa Barbaro)
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · CancerTrials@nyulangone.org
    Contact: Principal Investigator (Marissa Barbaro)
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162
    Contact: Principal Investigator (Aya Haggiagi)
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · 800-804-9376
    Contact: Principal Investigator (Ashley L. Sumrall)
  • Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · 336-713-6771
    Contact: Principal Investigator (Roy E. Strowd)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (Hamid R. Mohtashami)
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (James D. Battiste)
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · 412-647-8073
    Contact: Principal Investigator (Megan Mantica)
  • Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Site Public Contact) · 800-811-8480
    Contact: Principal Investigator (Alexander C. Mohler)
  • Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

    Contact: Study coordinator (Site Public Contact) · cancerinfo@hci.utah.edu · 888-424-2100
    Contact: Principal Investigator (Joe S. Mendez)
  • VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · CTOclinops@vcu.edu · 804-628-6430
    Contact: Principal Investigator (Mariza Daras)
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Brett A. Morris)
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Brett A. Morris)
Study leads
  • Stephanie M Yoon

    Principal Investigator

    City of Hope Comprehensive Cancer Center LAO